术前使用他类药物可以降低术前非Q波心肌梗塞的程度
Joerg Herrmann1, Amir Lerman, Dietrich Baumgart
1Department of Cardiology, University Clinic Essen, Essen, Germany.
Circulation
|October 23, 2002
概括
术前的他类药物治疗显著降低了冠状动脉支架后主要心肌损伤的风险. 这种心脏保护作用凸显了他类药物在干预心脏病学中的重要性.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学 是一个学科.
背景情况:
- 与支架相关的心肌损伤很常见,与微循环问题,血小板聚合,炎症和氧化应激有关.
- 除了降低脂质之外,3-基-3-甲基氨酸辅酶A (HMG-CoA) 减少酶抑制剂 (他类药物) 具有抗血栓,抗炎和抗氧化特性.
研究的目的:
- 为了调查前程序性他类药物治疗可以减少与冠状动脉支架相关的心肌损伤的程度的假设.
主要方法:
- 296名接受支架治疗的患者被分为治疗他类药物 (229) 和对照 (67) 组.
- 在干预后的多个时间点,肌心损伤被评估为肌酸激酶 (CK) 和心脏热素T (cTnT) 水平.
- 统计分析确定了与心肌损伤相关的因素.
主要成果:
- 在接受他治疗的患者中,肌酸激酶升高的发生率大于正常的上限的3倍,降低了90%以上 (0.4%对6.0%,P=0.01).
- 达丁类药物治疗是降低CK升高>3xULN (OR:0.08,95%CI:0.01至0.75,P=0.03) 的唯一独立预测因素.
- 在他类药物组中,CK和cTnT升高的总发病率略低,但没有统计学意义 (P=0.3和P=0.5,分别).
结论:
- 术前使用他类药物与在支架后发生较大的心肌梗塞的发病率降低有关.
- 建议进行进一步的随机试验,以确认在冠状动脉干预中使用他类药物的心脏保护益处.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:28Cardiac Catheterization I: Pre-Procedure Overview
3.4K
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
3.4K
01:27Coronary Artery Disease V: Interprofessional Care
450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
01:28Acute Coronary Syndrome IV: Interprofessional Care
525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525
01:26Angina IV: Management
495
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
495
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747